FOLH1 and prostate carcinoma: It is exciting to speculate that human sialidases could be conjugated to other antibodies, including, for example, a prostate-specific membrane antigen (PSMA) antibody, to selectively de-sialylate prostate cancer cells and induce an anti-tumour immune response.